Breaking News

Dollar Tree Agrees to Buy Family Dollar for $74.50 a Share
Tweet TWEET

Stereotaxis Announces Listing Transfer to NASDAQ Capital Market

Stereotaxis Announces Listing Transfer to NASDAQ Capital Market

ST. LOUIS, Aug. 16, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
today announced that it received a positive determination from the NASDAQ
Listing Qualifications Panel (the "Panel") on August 15, 2013 granting
approval of the Company's request to transfer its listing to The NASDAQ
Capital Market^® from The NASDAQ Global Market^®. The Company's securities
will begin trading on the NASDAQ Capital Market effective at the start of
trading on Monday, August 19, 2013.The transfer of the Company's listing to
The NASDAQ Capital Market is not expected to have any impact on trading in the
Company's shares, and the Company's shares will continue to trade on NASDAQ
under the symbol STXS.

As previously disclosed, on July 25, 2013, the Company appeared before the
Panel and requested the transfer of its listing from The NASDAQ Global Market
to The NASDAQ Capital Market, pursuant to a plan to evidence compliance with
the requirements for continued listing on The NASDAQ Capital Market.Following
the hearing, the Panel determined that the Company appears to have evidenced
compliance with those requirements.The Company's continued listing on The
NASDAQ Capital Market is subject to the submission of a transfer application
to NASDAQ and approval of the application by the NASDAQ Listing Qualifications
Staff.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core Epoch™
Solution includes the Niobe^® ES Remote Magnetic Navigation system, the
Odyssey^® portfolio of lab optimization, networking and patient information
management systems and the Vdrive^™ Robotic Mechanical Navigation system and
consumables.

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Sono^™ ICE catheter
manipulator has received U.S. clearance, and the V-Loop™ circular catheter
manipulator is currently in clinical trials in order to obtain clearance by
the U.S. Food and Drug Administration. For more information, please visit
www.stereotaxis.com

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability to
raise additional capital or otherwise address ongoing liquidity challenges on
a timely basis and on terms that are acceptable, its ability to continue to
manage expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance indebtedness on
acceptable terms or at all, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the ability and
willingness of customers to purchase its systems and the timing of such
purchases, the outcome of various shareholder litigation filed against
Stereotaxis, competitive factors, changes resulting from the recently enacted
healthcare reform in the U.S., including changes in government reimbursement
procedures, dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and other
filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue related to
its purchase orders and other commitments in any particular period or at all
because some of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In addition, these
orders and commitments may be revised, modified, delayed or canceled, either
by their express terms, as a result of negotiations, or by overall project
changes or delays.

CONTACT: Company Contact:
         Marty Stammer
         Chief Financial Officer
         314-678-6155
        
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300
         stxs@mkr-group.com